Method of treating sweat-related conditions using finasteride, epristeride and a cholestan-3-one
AssigneeMerck & Co., Inc.
InventorJoanne Waldstreicher
Life of this patent
Estimating the term…
Abstract
The instant invention involves methods of treating sweat related conditions with compounds that are 5.alpha.-reductase inhibitors. The 5.alpha.-reductase inhibitors may be administered alone or in combination with other active agents to treat conditions such as apocrine gland sweating, hyperhidrosis, and hydradenitis suppurativa.
Claims14
A pharmaceutical composition comprising
- (a) a pharmaceutically acceptable carrier,
- (b) a therapeutically effective amount of a 5.alpha.-reductase inhibitor selected from finasteride, epristeride or 4,7.beta.-dimethyl-4-aza-5.alpha.-cholestan-3-one, and
- (c) a therapeutically effective amount of an antiperspirant.
A pharmaceutical composition comprising
- (a) a pharmaceutically acceptable carrier,
- (b) a therapeutically effective amount of the 5.alpha.-reductase type 1 inhibitor, 4,7.beta.-dimethyl-4-aza-5.alpha.-cholestan-3-one and a 5.alpha.-reductase type 2 inhibitor selected from finasteride and epristeride, or
- (c) a therapeutically effective amount of an antiperspirant.
A method of treating a condition selected from apocrine gland sweating, hyperhidrosis, or hydradenitis suppurativa comprising adminstering to a person in need of such treatment a therapeutically effective amount of a 5.alpha.-reductase inhibitor selected from finasteride, epristeride or 4,7.beta.-dimethyl-4-aza-5.alpha.-cholestan-3-one.
Dependencies are inferred from the claim text.